CYP3A4 and Hyperkalemia: In a previous case report, rhabdomyolysis occurred following combined administration of CYP3A4-metabolized statins and diltiazem.14 Patel et al had reported that coprescription of CYP3A4-metabolized statins and CYP3A4 inhibitors increased the risk of rhabdomyolysis, acute kidney injury, and hyperkalemia.3 In this study, we had found a higher risk of acute kidney injury and hyperkalemia following the coprescription of CYP3A4-matabolized statins and CCB.